AU2016374365B2 - Treatment of intrahepatic cholestasis and related liver diseases - Google Patents

Treatment of intrahepatic cholestasis and related liver diseases Download PDF

Info

Publication number
AU2016374365B2
AU2016374365B2 AU2016374365A AU2016374365A AU2016374365B2 AU 2016374365 B2 AU2016374365 B2 AU 2016374365B2 AU 2016374365 A AU2016374365 A AU 2016374365A AU 2016374365 A AU2016374365 A AU 2016374365A AU 2016374365 B2 AU2016374365 B2 AU 2016374365B2
Authority
AU
Australia
Prior art keywords
activity
bacterial strain
bacterial
bile acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2016374365A
Other languages
English (en)
Other versions
AU2016374365A1 (en
Inventor
Fredrik Karlsson
Bo MÖLLSTAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabogen AB
Original Assignee
Metabogen AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabogen AB filed Critical Metabogen AB
Publication of AU2016374365A1 publication Critical patent/AU2016374365A1/en
Application granted granted Critical
Publication of AU2016374365B2 publication Critical patent/AU2016374365B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016374365A 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases Expired - Fee Related AU2016374365B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562266771P 2015-12-14 2015-12-14
US62/266,771 2015-12-14
PCT/EP2016/080941 WO2017102816A1 (en) 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases

Publications (2)

Publication Number Publication Date
AU2016374365A1 AU2016374365A1 (en) 2018-07-12
AU2016374365B2 true AU2016374365B2 (en) 2023-04-13

Family

ID=57570064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016374365A Expired - Fee Related AU2016374365B2 (en) 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases

Country Status (16)

Country Link
US (1) US20180369297A1 (https=)
EP (1) EP3389680B1 (https=)
JP (2) JP2018537484A (https=)
KR (1) KR20180094950A (https=)
CN (1) CN109069548A (https=)
AU (1) AU2016374365B2 (https=)
BR (1) BR112018012022A2 (https=)
CA (1) CA3008195A1 (https=)
CL (1) CL2018001548A1 (https=)
ES (1) ES2962302T3 (https=)
IL (1) IL259480B2 (https=)
MX (1) MX2018007227A (https=)
RU (1) RU2743405C2 (https=)
SG (1) SG11201804255QA (https=)
WO (1) WO2017102816A1 (https=)
ZA (1) ZA201804660B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
CN112280720B (zh) * 2020-11-19 2021-07-13 山东龙昌动物保健品有限公司 一株多形拟杆菌gl-02及其与胆汁酸复配的复合菌剂与应用
US20240122996A1 (en) * 2021-02-08 2024-04-18 Liscure Biosciences Co., Ltd. Pharmaceutical composition for preventing or treating cholestatic liver injury comprising leuconostoc citreum strain as active ingredient
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
GB2628547A (en) * 2023-03-27 2024-10-02 Univ Newcastle Probiotic and postbiotic compositions, products and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093619A1 (en) * 2006-02-15 2007-08-23 Nestec S.A. Use of bifidobacterium longum for the prevention and treatment of inflammation
US20110217759A1 (en) * 1996-03-11 2011-09-08 Claudio De Simone Strains of bacteria and pharmaceutical composition containing one or more of such strains and use of same for preventing and treating diseases associated with or caused by altered metabolism of bile acids

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4905300A (en) * 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20120128633A1 (en) * 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
CN102539791A (zh) * 2012-01-09 2012-07-04 宁波天康生物科技有限公司 总胆汁酸的定量测定及测定试剂盒
CA2926466C (en) * 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110217759A1 (en) * 1996-03-11 2011-09-08 Claudio De Simone Strains of bacteria and pharmaceutical composition containing one or more of such strains and use of same for preventing and treating diseases associated with or caused by altered metabolism of bile acids
WO2007093619A1 (en) * 2006-02-15 2007-08-23 Nestec S.A. Use of bifidobacterium longum for the prevention and treatment of inflammation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Glantz, A. et al., 'Intrahepatic Cholestasis of Pregnancy: a Randomzied Controlled Trial Comparing Dexamethasone and Ursodeoxycholic Acid', Hepatology, (2005), vol. 42, no. 6, pages 1400-1405, doi: 10.1002/hep.20952. *
Lepercq, P. et al., 'Epimerization of chenodeoxycholic acid to ursodeoxycholic acid by clostridium', FEMS Microbiology Letters, (2004-06-01), vol. 235, no. 1, pages 65-72, doi:10.1016/j.femsle.2004.04.011. *

Also Published As

Publication number Publication date
RU2018124487A3 (https=) 2020-05-29
KR20180094950A (ko) 2018-08-24
CL2018001548A1 (es) 2018-07-20
RU2743405C2 (ru) 2021-02-18
MX2018007227A (es) 2018-08-01
ES2962302T3 (es) 2024-03-18
JP2018537484A (ja) 2018-12-20
BR112018012022A2 (pt) 2018-12-04
IL259480A (en) 2018-07-31
JP2022166039A (ja) 2022-11-01
WO2017102816A1 (en) 2017-06-22
US20180369297A1 (en) 2018-12-27
RU2018124487A (ru) 2020-01-10
IL259480B1 (en) 2023-05-01
SG11201804255QA (en) 2018-06-28
CN109069548A (zh) 2018-12-21
AU2016374365A1 (en) 2018-07-12
IL259480B2 (en) 2023-09-01
CA3008195A1 (en) 2017-06-22
ZA201804660B (en) 2022-12-21
EP3389680C0 (en) 2023-10-11
EP3389680A1 (en) 2018-10-24
EP3389680B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
AU2016374365B2 (en) Treatment of intrahepatic cholestasis and related liver diseases
Baothman et al. The role of gut microbiota in the development of obesity and diabetes
Gorbach Estrogens, breast cancer, and intestinal flora
JP2013542195A5 (https=)
US5858998A (en) Budesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases
US20220378809A1 (en) Synthetic composition for balancing the bile acid profile in the intestine
Darvishi et al. Synbiotic supplementation improves metabolic factors and obesity values in women with polycystic ovary syndrome independent of affecting apelin levels: a randomized double-blind placebo-controlled clinical trial
Chen et al. Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support
US5891853A (en) Compositions and methods for enhancement of dehydroepiandrosterone
WO2017017677A1 (en) Combination treatment for liver disease
EP2266619B1 (de) Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung
Zhang et al. Microbial bile acid metabolite ameliorates mycophenolate mofetil-induced gastrointestinal toxicity through vitamin D3 receptor
Frezza et al. Prevention by S-adenosylmethionine of estrogen-induced hepatobiliary toxicity in susceptible women.
HK40002061A (en) Treatment of intrahepatic cholestasis and related liver diseases
RU2318538C1 (ru) Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение
Floreani et al. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis
EP1437140B1 (en) Oral pharmaceutical formulation containing active carbon and use of the same
US10398717B2 (en) Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating
Hassan et al. Development of bile acid biogenesis in the rat: effect of neonatal thyroidectomy, adrenalectomy, and streptozotocin-induced diabetes
Parekh et al. The Role of Gut Microflora in Obesity-Does the Data Provide an Option for Intervention?
ITMI971372A1 (it) Medicamento utile per ridurre la massa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella seconda
Ventura et al. A double-blind controlled trial of the efficacy and safety of taurohyodeoxycholic acid in the treatment of dyspeptic disturbances associated with gallstones or other hepatic disorders
Orlic et al. Fetal rat utilization of 55Fe absorbed by fetal intestine from swallowed amniotic fluid
US3446895A (en) Methods for treating muscular dystrophy with a 1-methyl-delta**1-androsten-17beta-ol-3-one and digitoxin
CN120227389A (zh) 一种猴菇多糖的用途

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee